$WUXI APPTEC(02359.HK)

WuXi AppTec (2359.HK) has once again become the focus of market attention recently. In the past few days, the third-quarter report showed impressive data: net profit attributable to the parent company in the first three quarters increased by 84.84% year-on-year, and total revenue achieved double-digit growth, which made many investors exclaim "blockbuster performance." However, there is also some lesser-known news: on November 3, the net outflow of main funds exceeded HKD 860 million, accounting for nearly 16% of the day's turnover. Interestingly, some brokerages have raised their target prices. For example, CCB International raised its target to HKD 131, optimistic about the strong drive from the TIDES (chemical conjugates) business and believes overseas order demand can continue to rise. At the industry level, although the "Biosecurity Bill 2.0" has put pressure on the sector, major institutions generally believe that this pullback has laid a good foundation for next year's performance, and WuXi AppTec remains one of the preferred targets. What do you think of this combination of strong performance, capital outflow, and valuation increase with lingering concerns? Will you choose to buy more as it falls, or wait for clearer signals before acting?